查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1766265

人類乳突病毒疫苗市場機會、成長動力、產業趨勢分析及 2025 - 2034 年預測

Human Papillomavirus Vaccines Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025 - 2034
出版日期: | 出版商: Global Market Insights Inc. | 英文 130 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

2024年，全球人類乳突病毒疫苗市場規模達54億美元，預計到2034年將以10.1%的複合年成長率成長，達到141億美元。這一成長主要源自於HPV感染發生率的上升，HPV感染是全球子宮頸癌、肛門癌、口咽癌和其他肛門生殖器癌的原因。人們對HPV相關癌症的認知不斷提高，以及疫苗接種計劃的重要性日益凸顯，進一步推動了市場成長。已開發國家和發展中國家HPV相關疾病負擔的不斷加重，加上公共衛生部門為推廣廣泛免疫接種和子宮頸癌治療所做的努力，是推動市場成長的重要因素。

人類乳突病毒疫苗市場 - IMG1

此外，男性HPV感染率的上升以及性別中立疫苗接種策略的採用，擴大了目標族群，並刺激了HPV疫苗的需求。重組DNA技術和類病毒顆粒平台等疫苗技術的進步，正在推動下一代疫苗的開發，這些疫苗可提供更廣泛的保護和更持久的免疫力。此外，新興製造商正專注於本地生產，以提供價格合理的疫苗，滿足發展中地區日益成長的需求。 HPV疫苗市場以預防HPV感染的疫苗的開發、生產和分銷為中心，主要透過青少年和年輕人的免疫接種計劃進行。

市場範圍
起始年份 2024
預測年份 2025-2034
起始值 54億美元
預測值 141億美元
複合年成長率 10.1%

市場按類型細分為二價疫苗、四價疫苗和九價疫苗。 2024年，九價疫苗佔最大佔有率，價值39億美元。隨著人們對HPV相關癌症認知的提高，醫療保健提供者和政府優先考慮針對致癌性最強的HPV病毒株的疫苗。九價疫苗可預防九種高風險HPV類型（16、18、31、33、45、52和58型），提供更廣泛的覆蓋範圍，滿足關鍵的公共衛生需求。政府的免疫接種計劃在九價疫苗普及率的提高中發揮了關鍵作用。

2024年，女性市場佔據市場主導地位，預計複合年成長率將達到9.9%。由於HPV感染與子宮頸癌密切相關，疫苗接種計畫主要針對女性，以降低HPV相關疾病的發生率。公共衛生政策和國際建議強調女性免疫接種，這顯著刺激了需求。在公眾宣傳活動和非政府組織的支持下，女性健康意識和教育的增強，提高了女孩和年輕女性的疫苗接種率。父母和監護人日益成長的參與度也鞏固了這個市場的主導地位。

2024年，美國人乳突病毒疫苗市場規模達22億美元。美國HPV病例的不斷增加推動了對預防性疫苗的需求。公共衛生措施、高疾病負擔、強大的醫療基礎設施以及政府對預防性醫療保健的投入增加是推動市場成長的關鍵因素。性別中立的疫苗接種政策和學校免疫計劃持續推動美國國內的需求。

人類乳突病毒疫苗市場的主要參與者包括Inovio Pharmaceuticals、印度血清研究所、Recbio、葛蘭素史克、默克、沃森生物、Genexine、賽諾菲巴斯德、廈門萬泰和玉溪澤潤生物。 HPV疫苗市場的公司專注於創新，投資開發能夠提供更廣泛、更持久保護的下一代疫苗。與研究機構和生物技術公司的策略合作夥伴關係能夠加速產品開發和監管批准。

擴大生產能力並增強分銷網路有助於滿足全球日益成長的需求，尤其是在發展中地區。企業也透過與當地製造商合作來降低成本，優先考慮價格可負擔性和可及性。此外，有針對性的宣傳活動和倡導活動促進了疫苗的普及，支持了市場成長並增強了其全球影響力。

目錄

第1章：方法論與範圍

第2章：執行摘要

第3章：行業洞察

  • 產業生態系統分析
    • 供應商格局
    • 每個階段的增值
    • 影響價值鏈的因素
  • 產業衝擊力
    • 成長動力
      • HPV相關癌症盛行率上升
      • 日益轉向性別中立的疫苗接種政策
      • 不斷加強的認知與教育活動
      • 疫苗研發技術進步
    • 產業陷阱與挑戰
      • 先進疫苗成本高昂
      • 缺乏大規模免疫基礎設施
    • 市場機會
      • 擴大發展中國家的免疫計劃
      • 疫苗分發中的公私合作
  • 成長潛力分析
  • 監管格局
    • 北美洲
    • 歐洲
    • 亞太地區
  • 管道分析
  • 未來市場趨勢
  • 波特的分析
  • PESTEL分析

第4章：競爭格局

  • 介紹
  • 公司市佔率分析
  • 公司矩陣分析
  • 主要市場參與者的競爭分析
  • 競爭定位矩陣
  • 關鍵進展
    • 併購
    • 夥伴關係與協作
    • 新產品發布

第5章：市場估計與預測：按類型，2021 年至 2034 年

  • 主要趨勢
  • 二價
  • 四價
  • 九價

第6章：市場估計與預測：按適應症，2021 年至 2034 年

  • 主要趨勢
  • 子宮頸癌
  • 陰道癌及外陰癌
  • 肛門癌
  • 口咽癌
  • 其他適應症

第7章：市場估計與預測：依性別，2021 年至 2034 年

  • 主要趨勢
  • 女性
  • 男性

第8章：市場估計與預測：按配銷通路，2021 年至 2034 年

  • 主要趨勢
  • 醫院藥房
  • 零售藥局
  • 網路藥局

第9章：市場估計與預測：按地區，2021 年至 2034 年

  • 主要趨勢
  • 北美洲
    • 美國
    • 加拿大
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 西班牙
    • 義大利
    • 荷蘭
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 澳洲
    • 韓國
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國

第10章：公司簡介

  • Genexine
  • GlaxoSmithKline
  • Inovio Pharmaceuticals
  • Merck
  • Recbio
  • Sanofi Pasteur
  • Serum Institute of India
  • Walvax Biotechnology
  • Xiamen Innovax
  • Yuxi Zerun Biotech
簡介目錄
Product Code: 14103

The Global Human Papillomavirus Vaccines Market was valued at USD 5.4 billion in 2024 and is estimated to grow at a CAGR of 10.1% to reach USD 14.1 billion by 2034. This expansion is largely driven by the rising incidence of HPV infections, which contribute to cervical, anal, oropharyngeal, and other anogenital cancers worldwide. Increasing awareness about HPV-related cancers and the importance of vaccination programs is further propelling market growth. The rising burden of HPV-associated diseases in both developed and developing countries, coupled with public health efforts to promote widespread immunization and cervical cancer treatment, is a significant growth factor.

Human Papillomavirus Vaccines Market - IMG1

Additionally, the increasing prevalence of HPV infections in men and the adoption of gender-neutral vaccination strategies are broadening the target population and boosting demand for HPV vaccines. Advances in vaccine technology, such as recombinant DNA techniques and virus-like particle platforms, are leading to the development of next-generation vaccines that offer broader protection and longer-lasting immunity. Moreover, emerging manufacturers are focusing on local production to provide affordable vaccines and meet growing demand in developing regions. The HPV vaccines market is centered around the development, manufacture, and distribution of vaccines that prevent HPV infections, primarily delivered through immunization programs targeting adolescents and young adults.

Market Scope
Start Year2024
Forecast Year2025-2034
Start Value$5.4 Billion
Forecast Value$14.1 Billion
CAGR10.1%

The market is segmented by type into bivalent, quadrivalent, and nonavalent vaccines. The nonavalent vaccine segment held the largest share in 2024, valued at USD 3.9 billion. Increased awareness of HPV-related cancers has led healthcare providers and governments to prioritize vaccines targeting the most oncogenic HPV strains. The nonavalent vaccine offers protection against nine high-risk HPV types (16, 18, 31, 33, 45, 52, and 58), providing a wider coverage that addresses critical public health needs. Government immunization initiatives have played a pivotal role in the increased adoption of nonavalent vaccines.

The female segment dominated the market in 2024 and is anticipated to grow at a CAGR of 9.9%. Since HPV infection is closely linked to cervical cancer, vaccination programs primarily target females to reduce the incidence of HPV-related diseases. Public health policies and international recommendations have emphasized female immunization, which has significantly boosted demand. Enhanced awareness and education around women's health, supported by public campaigns and NGOs, have increased vaccine uptake among girls and young women. The growing involvement of parents and caregivers has also reinforced the dominance of this segment.

U.S. Human Papillomavirus Vaccines Market was valued at USD 2.2 billion in 2024. The rising number of HPV cases in the country drives the need for preventive vaccines. Public health initiatives, a high disease burden, robust healthcare infrastructure, and increased government investments in preventive healthcare are key factors fueling market growth. Gender-neutral vaccination policies and school-based immunization programs continue to push demand within the U.S.

Key players in the Human Papillomavirus Vaccines Market include Inovio Pharmaceuticals, Serum Institute of India, Recbio, GlaxoSmithKline, Merck, Walvax Biotechnology, Genexine, Sanofi Pasteur, Xiamen Innovax, and Yuxi Zerun Biotech. Companies in the HPV vaccines market focus on innovation by investing in the development of next-generation vaccines that provide broader and longer-lasting protection. Strategic partnerships with research institutions and biotechnology firms enable accelerated product development and regulatory approvals.

Expanding manufacturing capacities and enhancing distribution networks help meet rising global demand, especially in developing regions. Firms are also prioritizing affordability and accessibility by collaborating with local manufacturers to reduce costs. Additionally, targeted awareness campaigns and advocacy efforts promote vaccine adoption, supporting market growth and strengthening their presence worldwide.

Table of Contents

Chapter 1 Methodology and Scope

  • 1.1 Market scope and definitions
  • 1.2 Research design
    • 1.2.1 Research approach
    • 1.2.2 Data collection methods
  • 1.3 Data mining sources
    • 1.3.1 Global
    • 1.3.2 Regional/country
  • 1.4 Base estimates and calculations
    • 1.4.1 Base year calculation
    • 1.4.2 Key trends for market estimation
  • 1.5 Primary research and validation
    • 1.5.1 Primary sources
  • 1.6 Forecast model
  • 1.7 Research assumption and limitations

Chapter 2 Executive Summary

  • 2.1 Industry 3600 synopsis
  • 2.2 Key market trends
    • 2.2.1 Regional
    • 2.2.2 Type
    • 2.2.3 Indication
    • 2.2.4 Gender
    • 2.2.5 Distribution channel
  • 2.3 CXO perspectives: Strategic imperatives
    • 2.3.1 Key decision points for industry executives
    • 2.3.2 Critical success factors for market players
  • 2.4 Future outlook and strategic recommendations

Chapter 3 Industry Insights

  • 3.1 Industry ecosystem analysis
    • 3.1.1 Supplier landscape
    • 3.1.2 Value addition at each stage
    • 3.1.3 Factor affecting the value chain
  • 3.2 Industry impact forces
    • 3.2.1 Growth drivers
      • 3.2.1.1 Rising prevalence of HPV-related cancers
      • 3.2.1.2 Increasing shift toward gender-neutral vaccination policies
      • 3.2.1.3 Growing awareness and education campaigns
      • 3.2.1.4 Technological advancements in vaccine development
    • 3.2.2 Industry pitfalls and challenges
      • 3.2.2.1 High cost of advanced vaccines
      • 3.2.2.2 Lack of infrastructure for mass immunization
    • 3.2.3 Market opportunities
      • 3.2.3.1 Expanding immunization programs in developing countries
      • 3.2.3.2 Public-private partnerships in vaccine distribution
  • 3.3 Growth potential analysis
  • 3.4 Regulatory landscape
    • 3.4.1 North America
    • 3.4.2 Europe
    • 3.4.3 Asia Pacific
  • 3.5 Pipeline analysis
  • 3.6 Future market trends
  • 3.7 Porter's analysis
  • 3.8 PESTEL analysis

Chapter 4 Competitive Landscape, 2024

  • 4.1 Introduction
  • 4.2 Company market share analysis
  • 4.3 Company matrix analysis
  • 4.4 Competitive analysis of major market players
  • 4.5 Competitive positioning matrix
  • 4.6 Key developments
    • 4.6.1 Merger and acquisition
    • 4.6.2 Partnership and collaboration
    • 4.6.3 New product launches

Chapter 5 Market Estimates and Forecast, By Type, 2021 – 2034 ($ Mn)

  • 5.1 Key trends
  • 5.2 Bivalent
  • 5.3 Quadrivalent
  • 5.4 Nonavalent

Chapter 6 Market Estimates and Forecast, By Indication, 2021 – 2034 ($ Mn)

  • 6.1 Key trends
  • 6.2 Cervical cancer
  • 6.3 Vaginal and vulvar cancer
  • 6.4 Anal cancer
  • 6.5 Oropharyngeal cancer
  • 6.6 Other indications

Chapter 7 Market Estimates and Forecast, By Gender, 2021 – 2034 ($ Mn)

  • 7.1 Key trends
  • 7.2 Female
  • 7.3 Male

Chapter 8 Market Estimates and Forecast, By Distribution Channel, 2021 – 2034 ($ Mn)

  • 8.1 Key trends
  • 8.2 Hospital pharmacies
  • 8.3 Retail pharmacies
  • 8.4 Online pharmacies

Chapter 9 Market Estimates and Forecast, By Region, 2021 – 2034 ($ Mn)

  • 9.1 Key trends
  • 9.2 North America
    • 9.2.1 U.S.
    • 9.2.2 Canada
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 France
    • 9.3.4 Spain
    • 9.3.5 Italy
    • 9.3.6 Netherlands
  • 9.4 Asia Pacific
    • 9.4.1 China
    • 9.4.2 Japan
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 South Korea
  • 9.5 Latin America
    • 9.5.1 Brazil
    • 9.5.2 Mexico
    • 9.5.3 Argentina
  • 9.6 Middle East and Africa
    • 9.6.1 South Africa
    • 9.6.2 Saudi Arabia
    • 9.6.3 UAE

Chapter 10 Company Profiles

  • 10.1 Genexine
  • 10.2 GlaxoSmithKline
  • 10.3 Inovio Pharmaceuticals
  • 10.4 Merck
  • 10.5 Recbio
  • 10.6 Sanofi Pasteur
  • 10.7 Serum Institute of India
  • 10.8 Walvax Biotechnology
  • 10.9 Xiamen Innovax
  • 10.10 Yuxi Zerun Biotech